Lymphocyte Subsets for Predicting Inflammatory Bowel Disease Progression and Treatment Response: a Systematic Review

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 4

PMID 39229260

Authors

Rirong Chen

Chao Li

Jieqi Zheng

Zinan Fan

Li Li

Minhu Chen

Baili Chen

Shenghong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Lymphocytes play a key role in the pathogenesis of inflammatory bowel disease (IBD) and are widely explored as promising prognostic indicators. We aimed to outline the existing evidences on the capability of lymphocyte subpopulations to predict disease progression and treatment response in patients with IBD.

Methods: The protocol for this review was registered in PROSPERO (registration ID: CRD 42022364126). Systematic retrieval was conducted using PubMed, Embase, and Web of Science databases. Original articles on the prognostic value of lymphocyte subsets in IBD published up to April 8, 2023 were eligible for inclusion. The Newcastle-Ottawa Scale was used to evaluate the risk of bias.

Results: Twenty studies were ultimately included: eight evaluated the prediction of disease progression and 12 focused on the prediction of treatment response. According to the Newcastle-Ottawa Scale, three studies were of high quality, 16 were of moderate quality, and only one was of low quality. T-cell subpopulations, including CD4 T cells, CD8 T cells, and γδ T cells, are revealed to have prognostic capacity. Transmembrane tumor necrosis factor α-bearing lymphocytes, CD4 T cells, CD8 T cells, and Plasma cells are found to have the potential to predict the response to anti-TNFα agents. In contrast memory T cells, CD4 T cells, and naïve B cells may predict the response to vedolizumab.

Conclusions: This systematic review identified several potential lymphocyte subset-related predictors. If verified in large cohort prospective studies, these findings could aid clinical decision-making.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022364126.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Smids C, Horjus Talabur Horje C, Drylewicz J, Roosenboom B, Groenen M, van Koolwijk E . Intestinal T Cell Profiling in Inflammatory Bowel Disease: Linking T Cell Subsets to Disease Activity and Disease Course. J Crohns Colitis. 2017; 12(4):465-475. DOI: 10.1093/ecco-jcc/jjx160. View

Solberg I, Vatn M, Hoie O, Stray N, Sauar J, Jahnsen J . Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5(12):1430-8. DOI: 10.1016/j.cgh.2007.09.002. View

Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R . Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8(4):244-50. DOI: 10.1097/00054725-200207000-00002. View

Duclaux-Loras R, Boschetti G, Flourie B, Roblin X, Leluduec J, Paul S . Relationships of circulating CD4 T cell subsets and cytokines with the risk of relapse in patients with Crohn's disease. Front Immunol. 2022; 13:864353. PMC: 9674020. DOI: 10.3389/fimmu.2022.864353. View

Imhann F, Vich Vila A, Bonder M, Fu J, Gevers D, Visschedijk M . Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2016; 67(1):108-119. PMC: 5699972. DOI: 10.1136/gutjnl-2016-312135. View

Chang J . Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med. 2020; 383(27):2652-2664. DOI: 10.1056/NEJMra2002697. View

Barre A, Colombel J, Ungaro R . Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018; 47(7):896-905. DOI: 10.1111/apt.14550. View

Dai S, Gu H, Lin Q, Wu Y, Wang X, Huang S . Decreased CD8+CD28+/CD8+CD28- T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease. Medicine (Baltimore). 2017; 96(26):e7247. PMC: 5500037. DOI: 10.1097/MD.0000000000007247. View

10.

Coletta M, Paroni M, Alvisi M, De Luca M, Rulli E, Mazza S . Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2020; 14(9):1190-1201. DOI: 10.1093/ecco-jcc/jjaa035. View

11.

Gisbert J, Chaparro M . Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2019; 14(5):694-709. DOI: 10.1093/ecco-jcc/jjz195. View

12.

Li Z, Vermeire S, Bullens D, Ferrante M, Van Steen K, Noman M . Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy. Inflamm Bowel Dis. 2015; 21(10):2418-28. DOI: 10.1097/MIB.0000000000000509. View

13.

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A . Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1785-94. DOI: 10.1053/j.gastro.2011.01.055. View

14.

Kadijani A, Aghdaei H, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H . Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2017; 8(9):e117. PMC: 5628358. DOI: 10.1038/ctg.2017.44. View

15.

Noor N, Lee J, Bond S, Dowling F, Brezina B, Patel K . A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024; 9(5):415-427. PMC: 11001594. DOI: 10.1016/S2468-1253(24)00034-7. View

16.

Gaffen S, Jain R, Garg A, Cua D . The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9):585-600. PMC: 4281037. DOI: 10.1038/nri3707. View

17.

Boland B, He Z, Tsai M, Olvera J, Omilusik K, Duong H . Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020; 5(50). PMC: 7733868. DOI: 10.1126/sciimmunol.abb4432. View

18.

Lee J, Lyons P, McKinney E, Sowerby J, Carr E, Bredin F . Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011; 121(10):4170-9. PMC: 3196314. DOI: 10.1172/JCI59255. View

19.

Ben-Horin S, Kopylov U, Chowers Y . Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2013; 13(1):24-30. DOI: 10.1016/j.autrev.2013.06.002. View

20.

Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris G . Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. J Crohns Colitis. 2022; 16(12):1882-1892. DOI: 10.1093/ecco-jcc/jjac100. View